Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor neoantigen-specific T cell
- Molecular classification
- T lymphocyte, CD8+ T cell, CD4+ T cell, Immune cell
01
Overview
Tumor neoantigen-specific T cells are a subset of T lymphocytes that recognize and respond to neoantigens—peptides derived from tumor-specific somatic mutations not present in normal tissues. These neoantigens are highly immunogenic because they arise from mutations unique to cancer cells, making them ideal targets for personalized cancer immunotherapy. These T cells can be either CD8+ (cytotoxic) or CD4+ (helper) subsets. Their presence and activity correlate with favorable clinical outcomes following therapies such as immune checkpoint blockade (ICB) and adoptive cell transfer (ACT).
02
Mechanism of action
Recognition of tumor-specific neoantigens presented on MHC molecules, leading to T cell activation and cytotoxic killing of tumor cells.
03
Biological functions
Adaptive immunityCytotoxicityT cell activationAntigen recognitionTumor cell lysisImmune response
04
Disease associations
CancerImmune response to tumors
05
Safety considerations
On-target, off-tumor toxicityCytokine release syndrome (CRS)Immune-related adverse events (irAEs)T cell exhaustionTumor immune evasionLoss of antigen presentation
06
Interacting drugs
Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab)
1 more in the full profile.
07
Biomarkers
Presence of tumor neoantigen-specific T cells in peripheral blood or tumor microenvironmentT cell receptor (TCR) sequence specific for neoantigenExpression of activation markers (e.g., PD-1, TIM-3) on neoantigen-specific T cellsNeoantigen load in tumorMHC Class I/II expression on tumor cells
Beyond the preview
Go deeper on Tumor neoantigen-specific T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor neoantigen-specific T cell.